Discontinue use if previous &/or serious hypersensitivity reactions (eg, anaphylaxis, angioedema) occur; pancreatitis is suspected & not to be restarted if confirmed. Not to be used in patients w/ type 1 DM or for diabetic ketoacidosis. Not recommended in patients w/ CHF NYHA class IV. Increased risk of hypoglycaemia; developing diabetic retinopathy complications. Acute pancreatitis. Potential risk of dehydration; MTC & thyroid tumor symptoms (eg, neck mass, dysphagia, dyspnea, persistent hoarseness). History of pancreatitis; angioedema or anaphylaxis w/ another GLP-1 receptor agonist. Patients w/ bariatric surgery. Closely monitor patients w/ diabetic retinopathy. May affect ability to drive & use machines when used w/ sulfonylurea or insulin. Severe renal & hepatic impairment. Not recommended in patients w/ ESRD. Women of childbearing potential should use contraception during treatment. Discontinue at least 2 mth before planned pregnancy. Not to be used during pregnancy & lactation. Childn & adolescents <18 yr. Elderly ≥75 yr.